Latest News
Eisai to appeal EU negative opinion on Alzheimer's drug
26 July 2024 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its partner Eisai Co Ltd (TYO:4523) announced on Friday that they intend to appeal the negative opinion on lecanemab for Alzheimer's disease from the Committee...
CStone wins EU approval for lung cancer drug
26 July 2024 - Biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) on Friday announced European Commission approval of sugemalimab (Cejemly) in combination with platinum-based chemotherapy for first-line treatment of non-small cell lung canc...
AbbVie receives EU approval for SKYRIZI in ulcerative colitis
26 July 2024 - Pharmaceutical research & development company AbbVie (NYSE:ABBV) on Friday announced European Commission approval for SKYRIZI (risankizumab) for the treatment of moderately to severely active ulcerative colitis (UC).SKYRIZI is targ...
Calliditas reports positive Phase 2b data
26 July 2024 - Swedish biopharma company Calliditas Therapeutics AB (STO:CALTX) on Friday reported positive topline data from its Phase 2b TRANSFORM trial evaluating setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC...
Cellectis secures FDA designations for UCART22
26 July 2024 - Clinical-stage biotechnology company Cellectis (Euronext Growth Paris:ALCLS) (NASDAQ:CLLS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designation for its UCAR...